Binding interactions of antagonists with 5-hydroxytryptamine3A receptor models

被引:42
作者
Maksay, G [1 ]
Bikádi, Z [1 ]
Simonyi, M [1 ]
机构
[1] Hungarian Acad Sci, Chem Res Ctr, Dept Mol Pharmacol, H-1025 Budapest, Hungary
关键词
5-HT3; receptor; species differences; homology modeling; docking of antagonists; tubocurarine; tropisetron; pharmacophore model;
D O I
10.1081/RRS-120025568
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Homology modeling was performed on the N-terminal extracellular regions of human, mouse, and guinea pig 5-hydroxytryptamine type 3A receptors (5-HT3R) based on the 24% sequence homology with and on the crystal structure of the snail acetylcholine binding protein (AChBP). Docking of 5-HT3 antagonists granisetron, tropisetron, ondansetron, dolasetron (setrons), and (+)-tubocurarine suggests an aromatic binding cleft behind a hydrophilic vestibule. Several intra- and interface interactions, H-bonds, and salt bridges stabilize the pentameric structure and the binding cleft. The planar rings of antagonists are intercalated between aromatic side-chains (W183-Y234, Y143-Y153). S227 donates H-bonds to the carbonyl groups of setrons. The tertiary ammonium ions interact with E236, N128 or E129, and/or W90 (cation-pi interaction). This offers a molecular explanation of the pharmacophore models of 5-HT3R antagonists. Docking artifacts suggest some ambiguities in the binding loops A and C of the 5-HT3AR models. Lower potencies of (+)-tubocurarine for human, and those of tropisetron for guinea pig 5-HT(3A)Rs can be attributed to steric differences of I/S230 in the binding cleft and to distinct binding interactions with E229 and S227, respectively. Ligand binding interferes with crucial intra- and interface interactions along the binding cleft.
引用
收藏
页码:255 / 270
页数:16
相关论文
共 36 条
[1]   Cation-π interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors:: The anomalous binding properties of nicotine [J].
Beene, DL ;
Brandt, GS ;
Zhong, WG ;
Zacharias, NM ;
Lester, HA ;
Dougherty, DA .
BIOCHEMISTRY, 2002, 41 (32) :10262-10269
[2]  
Belelli D, 1995, MOL PHARMACOL, V48, P1054
[3]   Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: Importance of glutamate 106 [J].
Boess, FG ;
Steward, LJ ;
Steele, JA ;
Liu, D ;
Reid, J ;
Glencorse, TA ;
Martin, IL .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :637-647
[4]   Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: A new homology modeling tool [J].
Bower, MJ ;
Cohen, FE ;
Dunbrack, RL .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (05) :1268-1282
[5]   Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors [J].
Brejc, K ;
van Dijk, WJ ;
Klaassen, RV ;
Schuurmans, M ;
van der Oost, J ;
Smit, AB ;
Sixma, TK .
NATURE, 2001, 411 (6835) :269-276
[6]   A 2ND GENERATION FORCE-FIELD FOR THE SIMULATION OF PROTEINS, NUCLEIC-ACIDS, AND ORGANIC-MOLECULES [J].
CORNELL, WD ;
CIEPLAK, P ;
BAYLY, CI ;
GOULD, IR ;
MERZ, KM ;
FERGUSON, DM ;
SPELLMEYER, DC ;
FOX, T ;
CALDWELL, JW ;
KOLLMAN, PA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (19) :5179-5197
[7]  
CORRINGER PJ, 2002, ANN REV PHARM TOXICO, V40, P431
[8]   Anxiety over GABAA receptor structure relieved by AChBP [J].
Cromer, BA ;
Morton, CJ ;
Parker, MW .
TRENDS IN BIOCHEMICAL SCIENCES, 2002, 27 (06) :280-287
[9]   The 5-HT3B subunit is a major determinant of serotonin-receptor function [J].
Davies, PA ;
Pistis, M ;
Hanna, MC ;
Peters, JA ;
Lambert, JJ ;
Hales, TG ;
Kirkness, EF .
NATURE, 1999, 397 (6717) :359-363
[10]   The non-antiemetic uses of serotonin 5-HT3 receptor antagonists - Clinical pharmacology and therapeutic applications [J].
Greenshaw, AJ ;
Silverstone, PH .
DRUGS, 1997, 53 (01) :20-39